| Literature DB >> 35718602 |
Hidetomi Terai1, Koji Tamai2, Shinji Takahashi1, Hiroshi Katsuda3, Nagakazu Shimada3, Yusuke Hori1, Yuto Kobayashi1, Hiroaki Nakamura1.
Abstract
BACKGROUND: Restrictions during the coronavirus disease 2019 (COVID-19) pandemic have decreased physical activity levels, which may result in locomotive syndrome. This study evaluated the change in locomotive syndrome prevalence and associated risk factors among an elderly population before and after a coronavirus outbreak.Entities:
Keywords: COVID-19; Locomotive syndrome; Onset; Prevalence; Stage
Year: 2022 PMID: 35718602 PMCID: PMC9167829 DOI: 10.1016/j.jos.2022.05.012
Source DB: PubMed Journal: J Orthop Sci ISSN: 0949-2658 Impact factor: 1.805
The GLFS-5 questionnaire items.
| Questionnaire item |
|---|
| 1. To what extent has it been difficult to go up and down stairs? |
| 2. To what extent has it been difficult to walk briskly? |
| 3. How far can you keep walking without rest? |
| 4. To what extent has it been difficult to carry objects weighing 2 kg? |
| 5. To what extent have load-bearing tasks and housework been difficult? |
GLFS-5, five-question Geriatric Locomotive Function Scale.
Fig. 1Flow chart of participant selection.
Distribution of GLFS-5 scores before and after the coronavirus disease 2019 outbreak.
| Score | LS grade | Pre-outbreak (March 2020) | Post-outbreak (July 2021) |
|---|---|---|---|
| 0 | Non-LS | 5364 (44.0) | 4486 (36.8) |
| 1 | 1748 (14.3) | 1969 (16.1) | |
| 2 | LS-1 | 1024 (8.4) | 1238 (10.2) |
| 3 | 808 (6.6) | 972 (8.0) | |
| 4 | LS-2 | 581 (4.8) | 701 (5.7) |
| 5 | 742 (6.1) | 667 (5.5) | |
| 6 | LS-3 | 333 (2.7) | 386 (3.2) |
| 7 | 245 (2.0) | 277 (2.3) | |
| 8 | 173 (1.4) | 215 (1.8) | |
| 9 | 132 (1.1) | 167 (1.4) | |
| ≥10 | 1047 (8.6) | 1119 (9.2) |
Numbers in parentheses indicate percentages.
GLFS-5, five-question Geriatric Locomotive Function Scale; LS-1, locomotive syndrome stage 1 (2–3 points); LS-2, locomotive syndrome stage 2 (4–5 points); LS-3, locomotive syndrome stage 3 (≥6 points).
Participant demographics according to whether LS developed after the coronavirus disease 2019 outbreak.
| Normal control | New-onset LS group | p-value | |
|---|---|---|---|
| Numbers | 6347 | 765 | |
| Age | <0.001 | ||
| 65–70 | 2962 (46.7) | 212 (27.7)∗ | |
| 71–75 | 1949 (30.7) | 238 (31.3) | |
| 76–80 | 997 (15.7) | 182 (23.8)∗ | |
| 81–85 | 349 (5.5) | 94 (12.3) ∗ | |
| ≥86 | 91 (1.4) | 39 (5.1)∗ | |
| Sex | <0.001 | ||
| Male | 3355 (52.9) | 344 (45.0)∗ | |
| Female | 2992 (47.1) | 421 (55.0)∗ | |
| Height (cm) | 160.9 ± 8.6 | 159.1 ± 9.1 | <0.001 |
| Weight (kg) | 59.0 ± 10.6 | 58.2 ± 12.0 | 0.055 |
| BMI | 22.7 ± 3.4 | 22.8 ± 3.5 | 0.262 |
| Daily exercise | <0.001 | ||
| Stable | 4096 (64.5) | 342 (44.7)∗ | |
| Increase | 169 (2.7) | 20 (2.6) | |
| Decrease | 1677 (26.4) | 346 (45.2)∗ | |
| No habit | 405 (6.4) | 57 (7.5) |
“Pre Normal–Post Normal” and “Pre Normal–Post LS” indicate the normal population and those with new-onset LS, respectively.
Continuous data are presented as the mean value ± standard deviation. Numbers in parentheses indicate percentages.
#One-way analysis of variance; †chi-squared test; ∗p < 0.05, residual analysis.
BMI, body mass index; LS, locomotive syndrome.
Risk factors for LS onset after the coronavirus disease 2019 outbreak.
| Objective variable: Individuals who developed LS after the outbreak | |||||
|---|---|---|---|---|---|
| Explanatory variables | Reference | aOR | p-value | 95% CI | |
| Age | >75 | 65 to 75 | 2.43 | <0.001 | 2.05–2.88 |
| Sex | Female | Male | 1.20 | 0.021 | 1.03–1.41 |
| BMI | <18 | 18 to 30 | 1.38 | 0.063 | 0.98–1.93 |
| >30 | 18 to 30 | 1.17 | 0.884 | 0.14–10.07 | |
| Regular exercise | Increase | Stable | 1.62 | 0.068 | 1.03–2.62 |
| Decrease | Stable | 2.52 | <0.001 | 2.14–3.00 | |
| No habit | Stable | 1.84 | <0.001 | 1.36–2.49 | |
aOR, adjusted odds ratio; BMI, body mass index; CI, confidence interval.
Participant demographics according to whether LS-3 newly developed after the coronavirus disease 2019 outbreak.
| LS-1/2 control group | New-onset LS-3 group | p-value | |
|---|---|---|---|
| Numbers | 2860 | 295 | |
| Age | <0.001 | ||
| 65–70 | 161 (5.6) | 11 (3.7) | |
| 71–75 | 629 (22.0) | 50 (16.9)∗ | |
| 76–80 | 912 (31.9) | 82 (27.8) | |
| 81–85 | 687 (24.0) | 75 (25.4) | |
| ≥86 | 471 (16.5) | 77 (26.1)∗ | |
| Sex | 0.407 | ||
| Male | 1157 (40.5) | 112 (38.0) | |
| Female | 1703 (59.5) | 183 (62.0) | |
| Height (cm) | 158.0 ± 8.4 | 156.8 ± 8.8 | 0.020 |
| Weight (kg) | 58.1 ± 15.8 | 57.5 ± 11.7 | 0.525 |
| BMI | 23.2 ± 5.2 | 23.3 ± 3.9 | 0.667 |
| Daily exercise | <0.001 | ||
| Stable | 1599 (55.9) | 106 (35.9)∗ | |
| Increased | 49 (1.7) | 6 (2.0) | |
| Decreased | 877 (30.7) | 147 (49.8)∗ | |
| No habit | 335 (11.7) | 36 (12.2) |
Continuous data are presented as the mean value ± standard deviation. Numbers in parentheses indicate percentages.
#One-way analysis of variance; †chi-squared test; ∗p < 0.05, residual analysis.
BMI, body mass index; LS-3, locomotive syndrome stage 3.
Risk factors for LS-3 onset after the coronavirus disease 2019 outbreak.
| Objective variable: Individuals who developed LS-3 after the outbreak | |||||
|---|---|---|---|---|---|
| Explanatory variables | Reference | aOR | p-value | 95%CI | |
| Age | >75 | 65 to 75 | 1.54 | 0.004 | 1.14–2.07 |
| Sex | Female | Male | 0.98 | 0.844 | 0.76–1.26 |
| BMI | <18 | 18 to 30 | 1.24 | 0.381 | 0.76–2.03 |
| >30 | 18 to 30 | 1.41 | 0.747 | 0.17–11.54 | |
| Regular exercise | Increase | Stable | 1.89 | 0.154 | 0.79–4.51 |
| Decrease | Stable | 2.59 | <0.001 | 1.98–3.37 | |
| No habit | Stable | 1.73 | 0.007 | 1.16–2.57 | |
aOR, adjusted odds ratio; BMI, body mass index; CI, confidence interval; LS-3, locomotive syndrome stage 3.
Comparison of musculoskeletal symptoms between participants who developed and did not develop LS after the coronavirus disease 2019 outbreak.
| Normal control (n = 6347) | New-onset LS group (n = 765) | p-value | |
|---|---|---|---|
| Back pain | |||
| Pre-pandemic | 1039 (16.4) | 224 (29.3) | <0.001 |
| Post-pandemic | 1100 (17.3) | 251 (32.8) | <0.001 |
| Newly emerging | 92 (1.4) | 34 (4.4) | <0.001 |
| Joint pain | |||
| Pre-pandemic | 186 (2.9) | 88 (11.5) | <0.001 |
| Post-pandemic | 215 (3.4) | 108 (14.1) | <0.001 |
| Newly emerging | 34 (0.5) | 20 (2.6) | <0.001 |
| Numbness | |||
| Pre-pandemic | 114 (1.8) | 37 (4.8) | <0.001 |
| Post-pandemic | 121 (1.9) | 44 (5.8) | <0.001 |
| Newly emerging | 9 (0.1) | 9 (1.2) | <0.001 |
Numbers in parentheses indicate percentages.
#One-way analysis of variance; †chi-squared test; ∗p < 0.05, residual analysis.
BMI, body mass index; LS, locomotive syndrome.
Comparison of musculoskeletal symptoms between participants who developed and did not develop LS-3 after the coronavirus disease 2019 outbreak.
| LS-1/2 control group (n = 2860) | New-onset LS-3 group (n = 295) | p-value | |
|---|---|---|---|
| Back pain | |||
| Pre-pandemic | 777 (27.2) | 109 (36.9) | 0.002 |
| Post-pandemic | 807 (28.2) | 112 (38.0) | 0.001 |
| Newly emerging | 48 (1.7) | 10 (3.4) | <0.001 |
| Joint pain | |||
| Pre-pandemic | 313 (10.9) | 64 (21.7) | <0.001 |
| Post-pandemic | 328 (11.5) | 67 (22.7) | <0.001 |
| Newly emerging | 19 (0.7) | 5 (1.7) | 0.067 |
| Numbness | |||
| Pre-pandemic | 151 (5.3) | 35 (11.9) | <0.001 |
| Post-pandemic | 154 (5.4) | 41 (13.9) | <0.001 |
| Newly emerging | 5 (0.2) | 6 (2.0) | <0.001 |
Numbers in parentheses indicate percentages.
#One-way analysis of variance; †chi-squared test; ∗p < 0.05, residual analysis.
BMI, body mass index; LS-3, locomotive syndrome stage 3.